Have you checked out the AUA/ASTRO/SUO’s recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management.

---

This podcast is supported by:

Veracyte

https://www.veracyte.com/decipher

---

SYNPOSIS

The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options.

This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions.

---

TIMESTAMPS

00:00 - Introduction

03:41 - Consensus Biochemical Recurrence Guidelines

08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management

13:24 - Patient Counseling and Risk of Recurrence

17:42 - PSMA PET Scans

20:44 - Postoperative PSA Monitoring

28:35 - The Role of Radiation

31:56 - Hormone Therapy

39:00 - Salvage Lymphadenectomy

46:30 - Future Directions and Concluding Thoughts

---

RESOURCES

Veracyte

https://www.veracyte.com/

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024)

https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer